Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.

We previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of 46 SNPs identified in Europeans and 3 SNPs from 8q24 shown to improve model performance in Africans. Herein, we used principal component (PC) analysis to uncover subpopulations of men with African ancestry for whom the utility of PHS46+African may differ.

Genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Genetic variation in a window spanning 3 African-specific 8q24 SNPs was estimated using 93 PCs. A Cox proportional hazards framework was used to identify the pair of PCs most strongly associated with the performance of PHS46+African. A calibration factor (CF) was formulated using Cox coefficients to quantify the extent to which the performance of PHS46+African varies with PC.

CF of PHS46+African was strongly associated with the first and twentieth PCs. Predicted CF ranged from 0.41 to 2.94, suggesting that PHS46+African may be up to 7 times more beneficial to some African men than others. The explained relative risk for PHS46+African varied from 3.6% to 9.9% for individuals with low and high CF values, respectively. By cross-referencing our data set with 1000 Genomes, we identified significant associations between continental and calibration groupings.

We identified PCs within 8q24 that were strongly associated with the performance of PHS46+African. Further research to improve the clinical utility of polygenic risk scores (or models) is needed to improve health outcomes for men of African ancestry.

Aldrich MC, Andreassen OA, Bensen JT, Blanchet P, Blot WJ, Brureau L, Bush WS, Cancel-Tassin G, Crawford DC, Cullen J, Cussenot O, Dale AM, Drake BF, Eeles RA, Fan CC, Fontham ETH, Fowke JH, Goodman PJ, Hu JJ, Huynh-Le MP, John EM, Karunamuni RA, Kibel AS, Kote-Jarai Z, Leach RJ, Lin HY, Lophatananon A, Lui A, Mahal B, Martinez ME, Menegaux F, Mills IG, Mohler JL, Muir K, Multigner L, Parent MÉ, Park JY, Petrovics G, Romana M, Rose BS, Sanderson M, Seibert TM, Tangen CM, Taylor JA, Thompson IM, Thompson W, Truong T, Zheng W

34127801

Prostate Cancer Prostatic Dis, 2021

Version 5.1.0